CG Oncology vs Taysha Gene Therapies
Taysha Gene Therapies is the larger business, with $9.8m of revenue in fiscal 2025 against $4.0m for CG Oncology (2.4 times as much). CG Oncology grew faster (254.7% against 17.3%). Taysha Gene Therapies kept more of each dollar of sales as profit: a net margin of -1115.3% against -3985.0%. CG Oncology carries less debt relative to equity (0.4% against 20.3%).
| Latest fiscal year | CG OncologyCGON, 2025 | Taysha Gene TherapiesTSHA, 2025 |
|---|---|---|
| Revenue | $4.0m | $9.8m |
| Revenue growth | 254.7% | 17.3% |
| Net income | −$161m | −$109m |
| Operating margin | -4722.1% | -1130.6% |
| Net margin | -3985.0% | -1115.3% |
| Return on equity | -21.7% | -68.5% |
| Free cash flow | −$132m | −$93.8m |
| Cash | $32.5m | $320m |
| Total debt | $3.0m | $50.1m |
| Debt to equity | 0.4% | 20.3% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 142 | 99 |
| Market value | $5.69bn | $1.32bn |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 1 buys, 17 sales | 0 buys, 12 sales |